Podcasts

Lipotoxicity in Type 2 Diabetes Faculty: Ralph DeFronzo, MD Learning About GLP-1 Agonist Therapy Faculty: For Your Patient A Succinct Summary of Available T2DM Therapies and How They Work Faculty: Ralph DeFronzo, MD Incretin Hormone Therapy Benefits Newly Diagnosed Type 2 Diabetes Patients Faculty: Ralph DeFronzo, MD Type 2 Diabetes: A Complicated Disease Faculty: Ralph DeFronzo, MD Initiating Insulin in Type 2 Diabetes Patients Faculty: For Your Patient Insulin Pump Technology: Improving Quality of Life in Diabetes Faculty: Juan Frias, MD Glucodynamic Effects With Co-formulations and Insulin Faculty: Juan Frias, MD What Does the Future Hold for the SGLT2-Inhibitor Class? Faculty: Robert R. Henry, MD New Longer-Acting Insulin Therapies Faculty: Juan Frias, MD Innovative Duros Delivery Device Faculty: Robert R. Henry, MD Beta-Cell Preservation: Reality or Wishful Thinking? Faculty: John B. Buse, MD, PhD A1c in the Post-ACCORD Era Faculty: John B. Buse, MD, PhD Pioglitazone and Bladder Cancer Faculty: John B. Buse, MD, PhD How Real is Cancer Risk With Certain Diabetes Medications? Faculty: John B. Buse, MD, PhD Does Bariatric Surgery Cure Type 2 Diabetes? Faculty: Dennis Kim, MD Future of Obesity Therapeutics and the FDA: An Experienced Perspective Faculty: Dennis Kim, MD Understanding GLP-1 Therapies and Blood Glucose Control Faculty: For Your Patient GLP-1 Agonists in Basal Insulin-Treated Type 2 Diabetes Patients Faculty: John Buse, MD, PhD SGLT-2 Update Faculty: John Buse, MD, PhD Hypoglycemia in the Setting of Type 2 Diabetes Faculty: John Buse, MD, PhD Successful Amylin Replacement Therapy for Your Type 2 Diabetes Patients Faculty: Patrick Boyle, MD Beta-Cell Function and the Treatment of Type 2 Diabetes Faculty: David Kendall, MD Review of the Potential of SGLT-2 Inhibitors Faculty: Robert Henry, MD Review of Reports on Relationship Between Insulin Glargine and Cancer Faculty: John Buse, MD, PhD